VOLITIONRX LTD — Director's Dealing 2020

Jul 23, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2020-07-21

Reporting Person: Reynolds Cameron John (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-21	Common Stock	M	50000	$2.5	Acquired	1176273	Direct
2020-07-21	Common Stock	F	40273	$3.95	Disposed	1136000	Direct
2020-07-21	Common Stock	M	50000	$3	Acquired	1186000	Direct
2020-07-21	Common Stock	F	43627	$3.95	Disposed	1142373	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-21	Stock Option (Right to Buy)	$2.5	M	50000	Disposed	2020-08-18	Common Stock (50000)	Direct
2020-07-21	Stock Option (Right to Buy)	$3	M	50000	Disposed	2020-08-18	Common Stock (50000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	34076	Indirect
Common Stock	1007718	Indirect

Footnotes

F1: Represents the aggregate number of shares of Common Stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction.

F2: The shares of Common Stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of Common Stock held by Concord International, Inc.